Sector
PharmaceuticalsOpen
₹1,509.2Prev. Close
₹1,509.2Turnover(Lac.)
₹5,086.6Day's High
₹1,530.05Day's Low
₹1,492.5552 Week's High
₹1,830.9552 Week's Low
₹959.05Book Value
₹865.85Face Value
₹1Mkt Cap (₹ Cr.)
42,764.2P/E
18.48EPS
81.65Divi. Yield
0.17This approval would allow Glenmark Therapeutics Inc., USA to market the product in the US market and would further fortify its ophthalmic portfolio.
Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.
The lawsuits included one on a generic version of Zetia, a cholesterol drug, as well as four other lawsuits involving Vytorin, a combination drug that contains Zetia.
EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency
It also appropriates ₹5.86 crore that Glenmark had already paid for surrendering IGST refunds relating to non-realisation of export proceeds.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 28.22 | 28.22 | 28.22 | 28.22 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 22,942.4 | 17,849.25 | 16,710.37 | 14,781.29 |
Net Worth | 22,970.62 | 17,877.47 | 16,738.59 | 14,809.51 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 7,567.93 | 6,712.63 | 6,403.23 | 7,989.23 |
yoy growth (%) | 12.74 | 4.83 | -19.85 | 30.64 |
Raw materials | -2,999.45 | -2,665.99 | -2,378.59 | -2,425.49 |
As % of sales | 39.63 | 39.71 | 37.14 | 30.35 |
Employee costs | -1,107.39 | -1,072.32 | -1,021.92 | -914.47 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 1,869.86 | 1,516.09 | 1,218.82 | 2,789.34 |
Depreciation | -150.81 | -138.53 | -118.2 | -104.93 |
Tax paid | -294.31 | -180.09 | -204.47 | -412.28 |
Working capital | 463.74 | -1,507.52 | -180.36 | 1,492.86 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.74 | 4.83 | -19.85 | 30.64 |
Op profit growth | 44.93 | -3.21 | -53.51 | 64.2 |
EBIT growth | 20.49 | 25.73 | -52.08 | 65.02 |
Net profit growth | 21.77 | 33.53 | -52.61 | 44.21 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 | 10,397.23 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 11,635.46 | 11,431.94 | 12,174.2 | 10,806.03 | 10,397.23 |
Other Operating Income | 177.64 | 151.3 | 130.71 | 137.9 | 243.74 |
Other Income | 1,237.32 | 755.86 | 166.67 | 94.76 | 192.48 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,713.65 | 130.56 | 4,11,306 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,666 | 72.52 | 1,50,342.82 | 594 | 0.53 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,452.35 | 25.21 | 1,17,322.54 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,207.1 | 59.54 | 1,08,614.11 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,421.9 | 51.66 | 99,891.45 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Glenn Saldanha
Executive Director (Corporate)
Cheryl Pinto
Executive Director & Group CFO
V S Mani
Non Executive Director
B E Saldanha
Independent Non Exe. Director
Rajesh Desai.
Independent Non Exe. Director
Sona Saira Ramasastry
Independent Non Exe. Director
Dipankar Bhattacharjee
Independent Non Exe. Director
V R Iyer
Additional Director
Pradeep Kumar Sinha
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Glenmark Pharmaceuticals Ltd
Summary
Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India.In the year 1979, the company entered dermatology market with the launch of Candid Cream. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril.In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded th
Read More
The Glenmark Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1515.45 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glenmark Pharmaceuticals Ltd is ₹42764.20 Cr. as of 02 Apr ‘25
The PE and PB ratios of Glenmark Pharmaceuticals Ltd is 18.48 and 1.78 as of 02 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Glenmark Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glenmark Pharmaceuticals Ltd is ₹959.05 and ₹1830.95 as of 02 Apr ‘25
Glenmark Pharmaceuticals Ltd's CAGR for 5 Years at 48.05%, 3 Years at 48.77%, 1 Year at 53.54%, 6 Month at -7.84%, 3 Month at -7.56% and 1 Month at 15.40%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.